Current management of c-KIT mutant melanoma involves clinical trials using a c-KIT inhibitor or immunotherapy, as there is currently minimal data for the efficacy of immune-modulators in c-KIT mutant melanomas [140]. This evidence concerns the gene KIT and melanoma.